Newly released artificial intelligence (AI)-driven TissueMark software[1] empowers research labs to enhance quality and reliability, and reduce costs AMSTERDAM and VANCOUVER, British Columbia, March 15, 2018 -- Royal Philips (NYSE: PHG,...

By Christopher Ivicevich, Director of Regulatory Affairs & Quality Compliance, OptraSCAN With the recent shift in the industry as the result of this decision, a common question is “What lies in store for digital pathology system...

OptraSCAN has given tissuepathology.com a rare insight into their advisory board discussions as to what their thought leaders think is important in the digital pathology space for the market. OptraSCAN is of course the first On-Demand...

Promega Corporation intends to seek FDA approval and CE-IVD marking for a commercially available Microsatellite Instability (MSI) assay to assist oncologists and pathologists in determining colorectal cancer decisions. The current Promega...

I recently had an opportunity to speak with Esther Abels, Director of Regulatory, Clinical and Medical Affairs for Philips Digital Pathology Solutions about Philips’ recent approval to market their Philips Intellisite Pathology System (PIPS)...

Last month the FDA approved pembrolizumab (KEYTRUDA) for adult and pediatric patients with with metastatic or unresectable, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have...